News Sentiment

ORMP sentiment intelligence

Oramed Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.03 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

80/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 6

high-authority source matches

Trend context Trend active

-0.2% over one week, +3.9% over four weeks, trend active, and materially above fair value.

Latest direct headline Negative

Oramed stock trades quietly as diabetes pill strategy pivots after FDA setback

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 80/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 3.9% over four weeks
Fair value 58.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 40
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
TradingView 11
Stock Titan 8
Market source 7
simplywall.st 5
TradingKey 4
Seeking Alpha 3
PR Newswire 3
AD HOC NEWS 2

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 16
Balance sheet 4
Capital return 2
Guidance 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
TradingKey Direct company coverage

Oramed Pharmaceuticals Inc (ORMP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Oramed Pharmaceuticals Inc (ORMP), detailing its current price momentum, support and resistance levels, and various technical indicators and moving averages. The analysis suggests a "Sell" signal based on moving averages and indicator

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 07:38
Source
TradingKey
TradingKey Direct company coverage

Oramed Pharmaceuticals Inc (ORMP) Earnings Forecast: Future EPS & Revenue Growth Estimates

Oramed Pharmaceuticals Inc (ORMP) currently lacks an earnings forecast score, with the Biotechnology & Medical Research industry average being 8.13. Analyst forecasts set the price target at $3.25, with no deviation between high and low estimates. The company has not yet disclose

Tone
Neutral 50/100
Event
Earnings
Published
18 Jun 2026 06:38
Source
TradingKey
TradingKey Direct company coverage

Oramed Pharmaceuticals Inc (ORMP) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Oramed Pharmaceuticals Inc (ORMP), identifying major individual and institutional holders. It provides a breakdown of shareholder types and tracks institutional shareholding changes over several quarters, along with significant sh

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 14:10
Source
TradingKey
Associated Press Direct company coverage

Oramed: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
19 May 2026 21:36
Source
Associated Press